The global multiple sclerosis drugs market cagr in 2026 is witnessing notable expansion as the prevalence of multiple sclerosis increases and pharmaceutical companies intensify research and development activities for innovative therapies. Multiple sclerosis (MS) is an immune-mediated disease affecting the central nervous system and is characterized by inflammation, demyelination, progressive brain and spinal cord atrophy, and neuroaxonal loss. The number of people with multiple sclerosis globally increased from 2.3 million in 2013 to 2.8 million in 2020, increasing the demand for effective diagnosis and treatment options.
According to Fortune Business Insights, the global multiple sclerosis drugs market size was valued at USD 21.07 billion in 2025 and is projected to grow from USD 22.95 billion in 2026 to USD 53.20 billion by 2034, registering a CAGR of 11.08% over the forecast period. North America dominated the multiple sclerosis drugs market with a market share of 48.51% in 2025. The market is being supported by increasing R&D investment, product launches, government initiatives to improve treatment accessibility, and rising disease prevalence.
Significant research and development investment by pharmaceutical companies is one of the important factors supporting market growth. Research on neurological therapies has remained active, with companies investigating novel molecules and different mechanisms of action for multiple sclerosis treatment. Expanding clinical research and pipeline portfolios are expected to support the introduction of additional therapies.
Government support and recommendations are also contributing to market expansion. Governments and healthcare organizations have introduced guidelines, recommendations, and awareness initiatives concerning multiple sclerosis treatment. The Fortune Business Insights report highlights government recommendations concerning available MS therapies and funding for research aimed at developing innovative treatments.
However, high drug costs remain a key restraint. Multiple sclerosis treatments can involve substantial expenses, while increased out-of-pocket costs associated with disease-modifying therapies may affect treatment adherence and disease management. The report notes that the median yearly cost of disease-modifying therapy approached around USD 94,000 as of February 2022, according to data cited by Fortune Business Insights.
The competitive landscape is characterized by pharmaceutical companies working to strengthen their MS drug portfolios and expand treatment options. Product approvals and pipeline development remain important areas of competition. In August 2023, the U.S. FDA approved Tyruko (natalizumab), identified by Fortune Business Insights as the first biosimilar drug approved for the treatment of relapsing forms of multiple sclerosis.
Other developments highlighted in the report include Biogen's collaboration with InnoCare Pharma for Orelabrutinib, the European Commission's approval of a subcutaneous formulation of TYSABRI, and Janssen Pharmaceutical's FDA approval of Ponvory for adults with relapsing forms of MS.